Gemin X Pharmaceuticals

company

About

Gemin X Pharmaceuticals develops and commercializes targeted cancer therapeutics to improve the lives of patients.

  • 1 - 10

Details

Last Funding Type
Series C
Last Funding Money Raised
$38M
Industries
Biotechnology,Pharmaceutical,Therapeutics
Founded date
Jan 1, 1998
Number Of Employee
1 - 10
Operating Status
Active

Gemin X Pharmaceuticals is dedicated to the discovery, development and commercialization of novel, targeted cancer therapeutics to improve the lives of patients.

Gemin X's research on the Bcl-2 cell death regulation pathway has led to the discovery of GX15-070 (obatoclax), a novel small molecule that selectively reinitiates programmed cell death, or apoptosis, and may also be effective in inducing cancer cell self-digestion, or autophagy. Obatoclax has shown promising activity in both preclinical and early human clinical studies and is currently in Phase 2 clinical trials as both a single agent and combination therapy. Obatoclax has patent protection through 2025.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$62M
Gemin X Pharmaceuticals has raised a total of $62M in funding over 2 rounds. Their latest funding was raised on Aug 24, 2010 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 24, 2010 Series E $8M 1 Caxton Advantage Life Sciences Fund Detail
Apr 20, 2010 Series D $16M 1 Caxton Advantage Life Sciences Fund Detail
Jul 3, 2008 Series C $38M 3 Caxton Advantage Life Sciences Fund Detail

Investors

Number of Lead Investors
Number of Investors
3
3
Gemin X Pharmaceuticals is funded by 3 investors. Caxton Advantage Life Sciences Fund and Canadian Medical Discoveries Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Caxton Advantage Life Sciences Fund Yes Series E
Canadian Medical Discoveries Fund Series C
SB Life Science Series C